CNBC June 20, 2024
Key Points
– Gilead’s twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial.
– None of the roughly 2,000 women in the trial who received the lenacapavir shot contracted HIV.
– Gilead needs to replicate the results in another Phase 3 trial before seeking FDA approval. The company expects to share more data later this year or early next year.
– If the results are positive, lenacapavir for PrEP could reach the market as soon as late 2025.
Gilead‘s experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
None of the roughly 2,000 women in the trial who received the lenacapavir shot had contracted HIV by an interim analysis, prompting...
Today's Sponsors
Today's Sponsor